Insider trade

Officer sold ~$1.01M of JNJ shares in the open market

Traded Feb 27, 2026 · Filed Mar 3, 2026

Johnson & JohnsonJNJ

~$1.01M
Reported value · 4,075 sh @ $247.87: 24K
Holds after · shares reported: +4.1%
stock since the trade · S&P 500 +11.4%, $248.43 → $258.66 on Oct 1

Why it stands out

Johnson & Johnson's VP Corporate Controller sold $1.01M of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 27, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 3, 2026

Officer$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,010,070

Shares × reported transaction price

Timing vs results

37 days after results of Jan 21, 2026, 46 days before results of Apr 14, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $248.43 on Feb 27, 2026, at its 52-week high, after a 14% rise over the previous 30 trading days

52-week range $146.36 (May 14, 2025) to $248.43 (Feb 27, 2026), 100% of the way up, from 251 adjusted closes. 30 trading days earlier: $218.55 on Jan 14, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Prezcobix on Feb 27, 2026, the same day as this trade.

New use approved (efficacy supplement). Active ingredient: Cobicistat, Darunavir Ethanolate. From openFDA. Dates only; no link between the two is implied